James Yang Liu - 26 Mar 2025 Form 4 Insider Report for Oncocyte Corp (OCX)

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	OCX	Option to Purchase Common Stock	Award	$0	+10,000		$0.000000	10,000	26 Mar 2025	Common Stock	10,000	$3.18	Direct	F1
transaction	OCX	Restricted Stock Units	Award	$0	+18,867		$0.000000	18,867	26 Mar 2025	Common Stock	18,867	$0.000000	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Id	Content
F1	33 and 1/3% of the options will become exercisable after one year of continuous service from the effective date of grant, and the balance will become exercisable in 24 equal monthly installments commencing one year after the date of grant subject to continuous service through the applicable vesting date.
F2	33 and 1/3% of the restricted stock units will vest on each of the one-, two- and three-year anniversaries, respectively, of the effective date of grant subject to continuous service through the applicable vesting date.